Researchers from the University of Dundee have identified a biomarker signature which sheds new light on the molecular mechanisms underpinning lung cancer.
Lung cancer is both the most common cancer in the world, with an estimated 1.8 million new cases each year, and the most common cause of mortality from cancer in the world, responsible for 1.5 million deaths annually. Non-small cell lung cancer (NSCLC) is the major class, accounting for 80-90% of all cases.
Over 1,800 patients have been screened through the Stratified Medicine Programme Phase 2 (SMP2), with the 100th patient being recruited to the National Lung Matrix Trial (NLMT) in November 2016.
SMP2 is a national pre-screening study sponsored by Cancer Research UK, which stratifies patients with non-small-cell lung cancer for targeted therapy.
Following the recent review of the Adult and Paediatric ECMC Networks we are pleased to announce that we will be investing over £36 million into 18 adult locations across the UK, uniting world class cancer research and clinical expertise.
The National Lung Matrix Trial (NLMT) is the first UK trial to combine the development of a technology platform that screens for multiple genetic aberrations in tumours (provided by CRUK’s SMP2) with testing of multiple novel genetic-marker-directed drugs. The trial is focused on patients with advanced NSCLC and currently includes 8 drugs: 7 targeted treatments for patients with one of 20 molecular markers, and additionally a monoclonal antibody for the treatment of patients with no actionable mutations
The ECMC Programme Office work closely with the press team at Cancer Research UK (CRUK) to maximise the impact of the research that the Network supports.
Help us to identify ECMC-supported research by letting us know when you submit a paper or other outputs of your research. This ensures that the press team have the maximum amount of time to work with us to produce relevant press content.
Velindre Cancer Centre’s Clinical Trials Unit (CTU), which is part funded by the Cardiff ECMC, was recently shortlisted for an NHS Wales award.
The awards are an opportunity to showcase local health efforts and ensure improvement stays at the forefront of the NHS. The unit was selected as one of the three shortlisted candidates in the ‘Promoting Clinical Research and Application to Practice’ category for their efforts in giving patients access to new Phase I drugs.
A new study led by researchers at Glasgow ECMC will treat pancreatic cancer patients whose cancer has grown too big to be removed by surgery but has not yet spread to other parts of the body.
The team will give patients on the trial a drug called olaparib, in addition to the standard treatment of chemotherapy and radiation known as chemoradiation. The hope is that the combination will make the tumour small enough to be removed by surgery in these patients.
Researchers at Glasgow ECMC – in collaboration with the CRUK Clinical Trials Unit and Beatson West of Scotland Cancer Centre in Glasgow - are part of a UK-wide team that aim to evaluate the use of saracatinib (also known as AZD0530) as a new combination therapy for the treatment of advanced prostate cancer.